Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

akzo nobel pty limited - copper present as cuprous thiocyanate; zinc pyrithione - paint - copper present as cuprous thiocyanate cyanide active 125.0 g/l; zinc pyrithione mineral-zinc active 50.0 g/l - antifouling - boat - aluminium | aluminium boat - marine growth | barnacles | fresh-water fouling organisms | marine fouling organisms | mussels

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - yeast dried -

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

wfbm healthcare ltd - yeast plasmolysate - oral solution - 800microlitre/1ml

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - imidacloprid - suspension concentrate - imidacloprid guanidine active 350.0 g/l - insecticide - capsicum or pepper | cucurbit | eggplant | sugar cane - ratoon crop | sweet potato | tomato | cantaloupe | choko | cucumber | gh - childers canegrub | greyback canegrub | silverleaf whitefly | bemisia tabaci (biotype b) | cotton whitefly | poinsettia whitefly

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - imidacloprid - suspension concentrate - imidacloprid guanidine active 350.0 g/l - insecticide

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

crop care - imidacloprid(50g/kg) - granular - group 4a insecticide - sugar cane - plant crop - canegrub - lepidiota negatoria | childers canegrub | greyback canegrub | southern one-year canegrub | negatoria canegrub | southern 1 year canegrub

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - vitamin b12 = cyanocobalamin | vitamin b3 = nicotinamide | vitamin b5 calcium salt = calcium pantothenate | vitamin b2 = riboflavin | vitamin b1 hydrochloride = thiamine hydrochloride | vitamin b6 hydrochloride = pyridoxine hydrochloride | vitamin c = ascorbic acid | vitamin m = folic acid = pga | yeast dried - nutrition & metabolism - dog | bitch | castrate | puppy - vitamin | biotin deficiencies | detoxifying agent | erythropoietic activity | stamina | vitamin a | vitamin b | vitamin c | vitamin d | vitamin deficiencies | vitamin e | vitamin k

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

deseret biologicals - acetaldehyde (unii: go1n1zpr3b) (acetaldehyde - unii:go1n1zpr3b), coumarin (unii: a4vz22k1wt) (coumarin - unii:a4vz22k1wt), histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3), quercetin (unii: 9ikm0i5t1e) (quercetin - unii:9ikm0i5t1e), saccharomyces cerevisiae (unii: 978d8u419h) (saccharomyces cerevisiae - unii:978d8u419h), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), candida parapsilosis (unii: 0kz676d44n) (candida parapsilosis - unii:0kz676d44n), cortic - acetaldehyde 6 [hp_x] in 1 ml - temporary relief of symptoms related to yeast syndrome including fatigue, malaise, weakness, headaches, gi disturbance, depression and anxiety. temporary relief of symptoms related to yeast syndrome including fatigue, malaise, weakness, headaches, gi disturbance, depression and anxiety.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: monobasic sodium phosphate; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; aluminium hydroxide hydrate - engerix-b is indicated for active immunisation against hepatitis b virus infection. the nh&mrc* recommend all infants, young children and unvaccinated adolescents receive a primary course of immunisation against hepatitis b. the nh&mrc also recommends immunisation for persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis b virus. groups identified at increased risk of acquiring hbv infection include: infants born to carrier (hbsag-positive) mothers; individuals for whom post-exposure prophylaxis for hepatitis b is indicated; household contacts (other than sexual partners) of acute and chronic hepatitis b cases and carriers; susceptible sexual contacts. risk occurs in susceptible (anti-hbs negative) partners of hbv carriers and patients with acute hepatitis b; susceptible clients of std (sexually transmitted disease) clinics, and sexually active men who have sex with men are also at increased risk of infection; injecting drug users; haemodialysis patients, hiv-positive individuals and other immunosuppressed adults; patients receiving certain blood products especially patients with clotting disorders receiving blood product concentrates; individuals with chronic liver disease and / or hepatitis c; staff and residents of facilities for the intellectually disabled, including both residential and non-residential care of this group; liver transplant recipients. such individuals should be vaccinated prior to transplantation if seronegative for hepatitis b, as they may be at increased risk of infection from the transplanted organ; staff and inmates of long term correctional facilities; health care workers, dentists, embalmers, tattooists and body-piercers. all staff directly involved in patient care, embalming, or in the handling of human blood or tissue should be vaccinated; individuals adopting children from overseas. these children should be tested for hepatitis b, and if hbsag positive, members of the adoptive family should be vaccinated; others in whom vaccination may be justified include police, members of the armed forces and emergency services staff, depending on the risks of exposure associated with assigned duties. long term travellers to regions of high endemicity, and those residing for some time in such regions who may anticipate close personal contact with local residents, should be vaccinated. short-term tourists or business travellers are at very little risk of hepatitis b, provided they avoid exposure through sexual contact, injecting drug use, tattooing or body piercing. although the risk of hepatitis b infection in contact sports is low, immunisation of those involved should not be discouraged. as the risk in australian schools is very low, vaccination of classroom contacts is seldom indicated. nevertheless, vaccination of school children and adolescents should be encouraged; as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection, it can be expected that hepatitis d will also be prevented by vaccination with engerix-b. the vaccine will not protect against infection caused by hepatitis a, hepatitis c and hepatitis e viruses, and other pathogens known to infect the liver.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; aluminium hydroxide hydrate; sodium chloride; monobasic sodium phosphate; water for injections - engerix-b is indicated for active immunisation against hepatitis b virus infection. the nh&mrc* recommend all infants, young children and unvaccinated adolescents receive a primary course of immunisation against hepatitis b. the nh&mrc also recommends immunisation for persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis b virus. groups identified at increased risk of acquiring hbv infection include: infants born to carrier (hbsag-positive) mothers; individuals for whom post-exposure prophylaxis for hepatitis b is indicated; household contacts (other than sexual partners) of acute and chronic hepatitis b cases and carriers; susceptible sexual contacts. risk occurs in susceptible (anti-hbs negative) partners of hbv carriers and patients with acute hepatitis b; susceptible clients of std (sexually transmitted disease) clinics, and sexually active men who have sex with men are also at increased risk of infection; injecting drug users; haemodialysis patients, hiv-positive individuals and other immunosuppressed adults; patients receiving certain blood products especially patients with clotting disorders receiving blood product concentrates; individuals with chronic liver disease and / or hepatitis c; staff and residents of facilities for the intellectually disabled, including both residential and non-residential care of this group; liver transplant recipients. such individuals should be vaccinated prior to transplantation if seronegative for hepatitis b, as they may be at increased risk of infection from the transplanted organ; staff and inmates of long term correctional facilities; health care workers, dentists, embalmers, tattooists and body-piercers. all staff directly involved in patient care, embalming, or in the handling of human blood or tissue should be vaccinated; individuals adopting children from overseas. these children should be tested for hepatitis b, and if hbsag positive, members of the adoptive family should be vaccinated; others in whom vaccination may be justified include police, members of the armed forces and emergency services staff, depending on the risks of exposure associated with assigned duties. long term travellers to regions of high endemicity, and those residing for some time in such regions who may anticipate close personal contact with local residents, should be vaccinated. short-term tourists or business travellers are at very little risk of hepatitis b, provided they avoid exposure through sexual contact, injecting drug use, tattooing or body piercing. although the risk of hepatitis b infection in contact sports is low, immunisation of those involved should not be discouraged. as the risk in australian schools is very low, vaccination of classroom contacts is seldom indicated. nevertheless, vaccination of school children and adolescents should be encouraged; as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection, it can be expected that hepatitis d will also be prevented by vaccination with engerix-b. the vaccine will not protect against infection caused by hepatitis a, hepatitis c and hepatitis e viruses, and other pathogens known to infect the liver.